In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Perlegen raises $74mm in Series D placement

Executive Summary

Perlegen Sciences (pharmacogenetics; spun off of Affymetrix) has raised $74mm in its Series D private placement led by CSK Venture Capital. New investors Brookside Capital (managed by Bain Capital), Mizuho Securities, Glynn Capital, Cape Securities, and other US and European institutional investors participated, along with existing buyers Maverick Capital, Lombard Odier Darier Hentsch & Cie, Zesiger Capital, Sano Ventures, BSI SA, MPM BioEquities, SB Life Sciences, Unilever Ventures, Biofrontier Partners, Private Life Biomed, CMEA Ventures, Affymetrix (now holds a 30% stake), and individual investor Dr. Alex Zaffaroni.
Deal Industry
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

UsernamePublicRestriction

Register